GSE195843
The NFIB/CARM1 Axis is a Therapeutic Target for Small Cell Lung Cancer
We identified NFIB as a CARM1 substrate and showed that this transcription factor utilizes CARM1 as a coactivator. Importantly, NFIB harbors both oncogenic and metastatic activities, and is often overexpressed in small cell lung cancer (SCLC). Using a SCLC mouse model, we show that both CARM1 and the CARM1 methylation site on NFIB are critical for the rapid onset of SCLC. By performing the high-throughput sequecing analysis, we found that CARM1-null and NFIB-R388K mutant mouse SCLC tumors share the ability to regulate chromatin accessbility and have similar gene expression pattern. Overall design: Gene expression and chromatin accessbility profiles in WT, CARM1-null and NFIB-R388K mutant mouse SCLC tumors.